PRAXIS Resource Repository

Search our extensive library of COPD care and readmissions reduction resources, including best practices, research articles, educational materials and toolkits.

Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD

Resource Type: Research Papers
1 Comments   |   Like 3 Likes

This matched case-control study of nationally representative administrative data examined the relationship between treatment using arformoterol or nebulized SABA and 30-day all-cause readmissions. Readmissions were significantly lower in the group treated with arformoterol than those using nebulized SABA, both before and after controlling for initial admission variables.

View Resource
Citation: Bollu V, Ernst FR, Karafilidis J, Rajagopalan K, Robinson SB, Braman SS. Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD. Int J Chron Obstruct Pulmon Dis. December 2013; (8): 631—639. DOI https://dx.doi.org/10.2147/COPD.S52557
exacerbations readmission treatment

1 Comments



You need to login to comment.
  • In my area, I feel arformoterol, a nebulized long-acting beta agonist, is under prescribed in comparison to SABA nebulizer medicines. Education for both healthcare professionals and patients is needed to bring greater awareness to LABA benefits in helping patients with COPD.
    Reply

Join Us on COPD360social

Sign In to Participate
Or register to become a member
1 in 40 Hospitalized